World PulseNow
Newsletter
Roche to Acquire 89bio for Up to $3.5 Billion, Expanding Focus on Liver Disease and Obesity Treatments
Financial MarketsRocheUpdated 5 hours ago

Roche to Acquire 89bio for Up to $3.5 Billion, Expanding Focus on Liver Disease and Obesity Treatments

Roche is set to acquire biopharmaceutical company 89bio for up to $3.5 billion, enhancing its portfolio in liver disease and obesity treatments. This strategic move underscores Roche's commitment to addressing significant health issues and advancing innovative therapies. The acquisition is expected to strengthen Roche's position in the biopharmaceutical market and improve patient outcomes worldwide.

Related Articles
Roche to acquire liver drug developer 89bio for up to $3.5 billion
Investing.coman hour ago
Roche to acquire liver drug developer 89bio for up to $3.5 billion
PositiveFinancial Markets
Roche's decision to acquire 89bio for up to $3.5 billion marks a significant move in the biotechnology sector, particularly in the development of liver disease treatments. This acquisition not only strengthens Roche's portfolio but also highlights the growing importance of innovative therapies in addressing unmet medical needs. The deal reflects confidence in 89bio's promising pipeline and could lead to advancements in patient care.
Read full article
via Investing.com
Roche to Buy 89bio for Up to $3.5 Billion in Obesity Push
Bloomberg5 hours ago
Roche to Buy 89bio for Up to $3.5 Billion in Obesity Push
PositiveFinancial Markets
Roche Holding AG is set to acquire biopharmaceutical company 89bio, Inc. for up to $3.5 billion, marking a significant step into the growing market for obesity treatments. This acquisition highlights Roche's commitment to addressing obesity and related health issues, which are becoming increasingly prevalent worldwide. By investing in 89bio, Roche aims to enhance its portfolio and provide innovative solutions for patients struggling with obesity.
Read full article
via Bloomberg
Swiss pharma giant Roche to buy US-listed 89bio for $2.4 bln in cash
Investing.com5 hours ago
Swiss pharma giant Roche to buy US-listed 89bio for $2.4 bln in cash
PositiveFinancial Markets
Swiss pharmaceutical giant Roche has announced its acquisition of US-listed 89bio for $2.4 billion in cash. This strategic move highlights Roche's commitment to expanding its portfolio in the biopharmaceutical sector, particularly in innovative treatments. The acquisition is expected to enhance Roche's capabilities in addressing unmet medical needs, which is crucial for maintaining its competitive edge in the industry.
Read full article
via Investing.com
Roche to acquire 89bio for up to $3.5 billion in liver disease push
Investing.com5 hours ago
Roche to acquire 89bio for up to $3.5 billion in liver disease push
PositiveFinancial Markets
Roche has announced its plan to acquire 89bio for up to $3.5 billion, marking a significant step in its efforts to enhance its portfolio in liver disease treatments. This acquisition is crucial as it not only strengthens Roche's position in the biopharmaceutical market but also highlights the growing focus on addressing liver diseases, which affect millions worldwide. The deal reflects Roche's commitment to innovation and improving patient outcomes.
Read full article
via Investing.com

Why World Pulse Now

Global Coverage

All major sources, one page

Emotional Lens

Feel the mood behind headlines

Trending Stories

Know what’s trending, globally

Read Less, Know More

Get summaries. Save time

Multi-Language

Switch languages to read your way

Save for Later

Your stories, stored for later

Live Stats

Our system has analyzed 5,122 articles worldwide

~213 per hour

614 trending stories shaping headlines

From breaking news to viral moments

Monitoring 200 trusted sources

Major outlets & specialized publications

Latest update 32 minutes ago

Always fresh

Learn moreHow it works